Continued momentum across General Medicines and Specialty

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended December 31, 2022. Revenue (from continuing operations) for the quarter came in at Rs 799 crores. PBT (before exceptional items) for the period (from continuing operations) at Rs 235 crores recorded a growth of 24%. EBITDA margins (from continuing operations) improved by 4.20%.

Revenue (from continuing operations) for the nine months ended December 31, 2022, came in at Rs 2434 crores. PBT (before exceptional items) from continuing operations for the nine months at Rs 656 crores recorded a growth of 12%. EBITDA from continuing operations at Rs 633 crores recorded a growth of 9%.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “General Medicines portfolio grew by 10% led by anti- infectives and dermatology therapies. Augmentin became the No.1 brand in the Indian Pharmaceutical Market (IPM) in 2022 (PharmaTrac AWACS). We continue to maintain market leadership in the therapy areas in which we operate.

Vaccine sales were down for the quarter in a declining self-pay vaccines market; however, we continue to gain market share for key vaccine brands."

During the quarter, the National List of Essential Medicines (NLEM), 2022, was announced. The list includes 16 GSK brands, of which revised prices have been notified for 8 brands. We will continue to drive various initiatives to mitigate the impact of the same.

The forthcoming launch of Shingrix - shingles vaccine (Herpes zoster) is GSK's next step towards driving innovation in India. Shingrix offers protection against this painful disease to everyone aged 50+ years including patients who are immunocompromised.

We will also introduce Calpol 650+ with novel Optizorb formulation.

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit